Age-Related Eye Disease Study 2 Ancillary Spectral Domain Optical Coherence Tomography Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Age Related Macular Degeneration
- Sponsor
- Duke University
- Enrollment
- 470
- Locations
- 4
- Primary Endpoint
- Primary outcome measures are the percent of eyes developing CNV, mean change in visual acuity, and change in drusen volume, area of GA and photoreceptor layer thickness from SDOCT centered on the fovea.
- Status
- Completed
- Last Updated
- 6 months ago
Overview
Brief Summary
The purpose of this study is to identify whether changes in age-related macular degeneration (AMD) over time as seen with spectral domain optical coherence tomography (SDOCT) imaging, can be used to predict vision loss and the advancement of AMD in people at moderate to high risk for progression.
Detailed Description
The primary objective of this study is to identify whether SDOCT patterns such as: drusen size, OCT reflectivity within drusen, photoreceptor (PR)change over drusen, microfoci of subretinal fluid (SRF), or retinal thickening are predictive of vision loss, progression of drusen, progression of photoreceptor loss over drusen, development of choroidal neovascularization (CNV), or development of geographic atrophy (GA). The secondary objectives of this study are: 1. To define the relationship between SDOCT imaging, autofluorescence (AF)imaging, and color photographic or other fundus imaging of AREDS 2 patients in both a cross-sectional study of baseline data and a longitudinal study in data collected over the 5 year AREDS 2 study. 2. To compare the extent of geographic atrophy on SDOCT versus color photographs and autofluorescence. 3. To evaluate whether the SDOCT outcome measures differ significantly between AREDS 2 patients randomized to different oral supplements in the AREDS2.
Investigators
Eligibility Criteria
Inclusion Criteria
- •AMD subjects and controls
- •Men and women between the ages of 50 and 85 years
- •AMD subjects
- •Enrollment in the AREDS 2 trial;
- •Macular status ranges from large drusen in both eyes or large drusen in one eye and advanced AMD (neovascular AMD or geographic atrophy) in the fellow eye
Exclusion Criteria
- •Ocular media not clear enough to allow good fundus photography.
Outcomes
Primary Outcomes
Primary outcome measures are the percent of eyes developing CNV, mean change in visual acuity, and change in drusen volume, area of GA and photoreceptor layer thickness from SDOCT centered on the fovea.
Time Frame: 2 years and 5 years
Secondary Outcomes
- Measurement of area of GA from SDOCT images versus color fundus photos versus AF images.(2 years and 5 years)
- Drusen area measured from SDOCT versus from color fundus photographs. Mean change in drusen area reproducibility of measurements using these techniques.(2 years and 5 years)
- Grading of drusen type, presence or absence of fluid, photoreceptor loss or retinal thickening from SDOCT versus from color fundus photographs at each timepoint.(2 years and 5 years)
- Correlation between SDOCT imaging and autofluorescence imaging and onset of geographic atrophy.(2 years and 5 years)
- To evaluate whether the SDOCT outcome measures differ significantly between AREDS 2 patients randomized to different oral supplements in the AREDS2.(5 years)